Navigation Links
Ivivi's PEMF Technology Significantly Improves Neuron Survival in,Parkinson's Disease Model, Study Finds

tic technologies as we intend to continue to develop our technology for this and other areas."

About Ivivi Technologies, Inc.

Based in Northvale, NJ, Ivivi Technologies, Inc. is a medical technology company focusing on designing, developing and commercializing its proprietary electrotherapeutic technology platform. Ivivi's research and development activities are focused specifically on pulsed electromagnetic field, or PEMF, technology, which, by creating a therapeutic electrical current in injured soft tissue, stimulates biochemical and physiological healing processes to help repair the injured tissue and reduce related pain and inflammation. The Company's Electroceuticals(TM) have been used in non-invasive treatments for a wide array of conditions, including chronic wounds, pain and edema following plastic and reconstructive surgery and chronic inflammatory disorders.

Forward-Looking Statements

This release contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including the statements related to the preliminary data discussed above. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, the Company's limited operating history, history of significant and continued operating losses and substantial accumulated earnings deficit, difficulties with its financial accounting controls, the failure of the market for the Company's products to continue to develop, the inability for c
'"/>




Page: 1 2 3

Related medicine technology :

1. West Nile Virus Screening and Diagnostics Technology Emerges In Step with North American Outbreak
2. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
5. Opexa Advances Monocyte Derived Islet Technology to Proof of Principle in stz-induced NOD/SCID Mice
6. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
7. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
10. Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with Electroporation DNA Delivery Technology and New Devices at Gene Therapy Meeting
11. Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology Shown to Significantly Lower Instances of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants
Post Your Comments:
(Date:8/31/2015)... 31, 2015 BioLight ... BLGTY) ("BioLight" or the "Company"), a firm that ... ophthalmology and cancer diagnostics, today announced that its ... identified several new genetic markers with high potential ... treated with bisphosphonate drugs and was able to ...
(Date:8/31/2015)... 31, 2015  Soligenix, Inc. (OTCQB: SNGX) ... developing products that address unmet medical needs in ... today it has completed enrollment of the additional ... (DRC) earlier this year, into the company,s Phase ... innate defense regulator (IDR) and is being evaluated ...
(Date:8/31/2015)... , Aug. 31, 2015  Asterias Biotherapeutics, Inc. ... the emerging field of regenerative medicine, today announced ... Chicago -based Rush University Medical ... activity of escalating doses of AST-OPC1 (oligodendrocyte progenitor ... motor complete cervical spinal cord injury (SCI). This ...
Breaking Medicine Technology:BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 2BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 3BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 2Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 3Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 5Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 6Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6
... experienced,clinical benefit when treated with daily RAD001 and monthly Sandostatin LAR ... Depot, - 77% of patients with pancreatic NET experienced clinical ... treated with daily RAD001, - Data show RAD001, an oral mTOR ... ...
... Inc.,(Nasdaq: BNVI ) today announced the publishing ... Society for Pharmacology and Experimental Therapeutics, Drug,Metabolism and ... Bioactive Compound Isolated from the Chinese Herbal,Selective Estrogen ... the active compounds of MF101, Bionovo,s drug,candidate for ...
Cached Medicine Technology:RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors 2RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors 3RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors 4RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors 5RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors 6RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors 7Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate 2Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate 3
(Date:8/31/2015)... ... August 31, 2015 , ... Move over shave cream. ... men and barbershops are scrambling to meet it. , Reports published this year (Mintel ... and haircare. But the data also reflects that men are getting more done at ...
(Date:8/31/2015)... ... 2015 , ... A year ago this month, Seniors Guide first hit stands ... issue commemorating the successful first year. , “We started the magazine with the ... in their lives,” says Melissa Wolfert, founding Publisher for Seniors Guide Columbus. “Making the ...
(Date:8/31/2015)... ... 2015 , ... Chicago-based company The Mood Factory, with brand ... and awareness for breast and ovarian health. During September and October, The ... to Bright Pink® to encourage households, dorms, and offices around the U.S. to ...
(Date:8/31/2015)... ... ... It’s a lot like coming home. Life-long Fox Valley resident James Holbrook has been ... the job, he’s run into residents of the retirement community who he’s known since ... in such a wonderful place,” he said. GreenFields, which is sponsored by Friendship Senior ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... networking and relationship-marketing firm, announced today the nominees vying for the 2015 ... U.S. Region. Executives include top-ranking decision makers representing national to global organizations ...
Breaking Medicine News(10 mins):Health News:MENAJI Anti-Aging Eraser a New Sure-Fire Add-On Product for Barbershops 2Health News:MENAJI Anti-Aging Eraser a New Sure-Fire Add-On Product for Barbershops 3Health News:Seniors Guide Magazine Celebrates Its First Year in Columbus With A Special Anniversary Issue 2Health News:Seniors Guide Magazine Celebrates Its First Year in Columbus With A Special Anniversary Issue 3Health News:Mood-lites® is proud to launch “Brighten Our World" Campaign to Raise Money and Awareness for Breast and Ovarian Health Across America in Partnership with Bright Pink® 2Health News:Mood-lites® is proud to launch “Brighten Our World" Campaign to Raise Money and Awareness for Breast and Ovarian Health Across America in Partnership with Bright Pink® 3Health News:Friendship Senior Options Welcomes New Executive Director for GreenFields of Geneva 2Health News:T.E.N. Announces Nominees for the 2015 ISE® Northeast Awards; People's Choice voting now open 2Health News:T.E.N. Announces Nominees for the 2015 ISE® Northeast Awards; People's Choice voting now open 3Health News:T.E.N. Announces Nominees for the 2015 ISE® Northeast Awards; People's Choice voting now open 4
... New research has found that hormone therapy used to treat ... chance of developing various heart problems. Some choices of therapy ... Researchers told Europe,s biggest cancer congress, ECCO 15 ESMO ... findings of their study, the largest and most comprehensive to ...
... , MAHWAH, N.J., Sept. 22 Radware ... application delivery solutions for business-smart networking, today announced ... and South Carolina, has leveraged Radware,s suite of application delivery solutions ... load balancing capabilities for its extensive hospital system. ...
... , , RANDOLPH, Mass., Sept. 22 ... to serving individuals with Autism Spectrum Disorders (ASD), today released its ... and adolescents with ASD ever published. , , ... information about the myriad treatments available for ASD," said Susan M. ...
... Germany, September 22 The,Gerresheimer Group expands its ... significant investments in the USA and,Europe. This week ... research,and development center for medical plastic systems in ... for pharmaceutical plastic packaging in Spain.,"Plastics are increasingly ...
... Corrie Yackulic, ... after nearly twenty years to open her own personal injury law practice. , ... Seattle, Wash. (Lexis Nexis) September 22, 2009 ... at personal injury law firm Schroeter Goldmark & Bender to launch her own personal injury ...
... ... Pelvic Organ Prolapse --provides helpful information about the common conditions of urinary incontinence and ... symptoms, as well as the symptoms of pelvic organ prolapse. Finally, treatment options are ... ...
Cached Medicine News:Health News:Prostate cancer patients on hormone therapy at increased risk for various heart diseases 2Health News:Prostate cancer patients on hormone therapy at increased risk for various heart diseases 3Health News:Prostate cancer patients on hormone therapy at increased risk for various heart diseases 4Health News:Radware Prevents Network Downtime for Carolinas HealthCare System, One of the Largest Healthcare Systems in the U.S. 2Health News:Radware Prevents Network Downtime for Carolinas HealthCare System, One of the Largest Healthcare Systems in the U.S. 3Health News:Radware Prevents Network Downtime for Carolinas HealthCare System, One of the Largest Healthcare Systems in the U.S. 4Health News:Radware Prevents Network Downtime for Carolinas HealthCare System, One of the Largest Healthcare Systems in the U.S. 5Health News:National Autism Center Releases Groundbreaking Report on Autism Treatments 2Health News:National Autism Center Releases Groundbreaking Report on Autism Treatments 3Health News:Gerresheimer Expands in the Global Pharmaceutical Plastic Business 2Health News:Gerresheimer Expands in the Global Pharmaceutical Plastic Business 3Health News:Seattle Personal Injury Attorney Corrie Yackulic Opens Law Firm, Unveils New Website 2Health News:Women's Pelvic Organ Prolapse and Incontinence Guide Informs, Outlines Treatments 2Health News:Women's Pelvic Organ Prolapse and Incontinence Guide Informs, Outlines Treatments 3
... sensitivity chart test face is the most widely ... test provides for four (4) rows of sine-wave ... ft (2.5 meters), these gratings test the spatial ... The CSV-1000E provides a full contrast sensitivity curve, ...
Contrast sensitivity testing, glare sensitivity testing and ETDRS acuity testing are provided in the self standardized CSV-1000 instrument. Patented photocell circuitry automatically monitors and cal...
The first book to translate key medical data into clear guidelines capturing the highest treatment standards for heart disease....
... Cochrane Reviews enable all those involved ... date with the very latest evidence in ... which becomes harder each year as the ... this problem by delivering the best single ...
Medicine Products: